What has NICE said?
Ombitasvir–paritaprevir–ritonavir (Viekirax) with or without dasabuvir (Exviera) is recommended as a possible treatment for adults with some types (called genotypes) of chronic hepatitis C. It is sometimes taken with ribavirin. See table 1.
Table 1 Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for adults with chronic hepatitis C
|
Type of hepatitis C |
Treatment recommended by NICE |
Length of treatment |
|
1a, without cirrhosis |
Ombitasvir–paritaprevir–ritonavir with dasabuvir and ribavirin |
12 weeks |
|
1a, with cirrhosis |
Ombitasvir–paritaprevir–ritonavir with dasabuvir and ribavirin |
24 weeks |
|
1b, without cirrhosis |
Ombitasvir–paritaprevir–ritonavir with dasabuvir |
12 weeks |
|
1b, with cirrhosis |
Ombitasvir–paritaprevir–ritonavir with dasabuvir and ribavirin |
12 weeks |
|
4, without cirrhosis |
Ombitasvir–paritaprevir–ritonavir with ribavirin |
12 weeks |
|
4, with cirrhosis |
Ombitasvir–paritaprevir–ritonavir with ribavirin |
24 weeks |
What does this mean for me?
If you have genotype 1 or 4 chronic hepatitis C, and your healthcare team think that ombitasvir–paritaprevir–ritonavir with or without dasabuvir is the right treatment, you should be able to have the treatment on the NHS.
The treatment should be available on the NHS within 3 months of the guidance being issued.